On the HCPLive Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.
September 14th 2023
An analysis of the Phoenix cohort provides insight into responder rates and treatment persistence with infliximab biosimilars among those with no previous exposure to biologics, a previous failure to respond to biologics, or those switching from reference infliximab.
IBD Trials Re-Randomizing Patients Had Higher Remission Rates
In recent years trial designs have evolved to become increasingly complex and sophisticated with new endpoints that could include patient-reported outcomes, biomarkers, mucosal, and histological healing, central endoscopy reading, and trials that examine both induction and maintenance of remission within the same study.
Guselkumab Bests Placebo in Clinical Remission for Ulcerative Colitis
Guselkumab induction treatment resulted in significantly greater proportions of patients achieving symptomatic remission, clinical response, endoscopy improvement, and histo-endoscopic mucosal improvement at week 12 and symptomatic remission at week 4 compared to placebo.
Infliximab Biosimilar Not Associated With Adverse Events in IBD
No statistically significant differences in infusion reaction, serious reaction, or immunogenicity rates were identified between patients switching to an infliximab biosimilar and those who continued treatment on the originator.
Ulcerative Colitis Patients in Remission Have Recovered Gut Microbiota
Patients in long-remission also presented with fecal bacterial composition that was similar to what was found in the healthy control group and there was a positive correlation between Akkermansia muciniphila abundance and time in remission.
Fasting, Food Exclusions Common for Patients With Inflammatory Bowel Disease
Disease activity and treatment with a small-molecule or an investigation drug were independently linked to an exclusion diet, while a history of stenosis and active disease were associated with fasting.
Obefazimod Results in Clinical Remission for Majority of Ulcerative Colitis Patients
The results show 52.5% of patients achieved clinical remission at week 96, while 59.0% saw endoscopic improvement, 35.9% achieved endoscopic remission, and 70.5% achieved a clinical response.
Bidirectional Montreal Classification Better Captures Crohn’s Disease Complications
Using the bidirectional Montreal classification system, which accounts for disease regression, showed that 90% of patients exhibited inflammatory disease behavior at 5 years, compared to 58% if the hierarchical, unidirectional Montreal classification system was implemented.
Weekly Folic Acid Supplementation Helps Maintain Folate Levels in IBD Patients
At the 6 month follow-up visit, all participants had stable folic acid levels without macrocytic anemia and the monthly questionnaires showed no increase in symptoms or adverse events reported.
Guselkumab, Golimumab Combination Therapy More Effective for Ulcerative Colitis Than Either Alone
The results show 83% of patients in the combination group achieved clinical response at week 12, compared to 61% of the golimumab monotherapy group and 75% of the guselkumab group.
Severe Acute Ulcerative Colitis Increases Risk of Pouchitis
Acute severe ulcerative colitis and a greater number of biologics precoloectomy were linked to an increased probability of acute pouchitis, while older age at colectomy was associated with a decreased probability of acute pouchitis.
An Increase in Infliximab Biosimilar Dose Escalation Results in Improved IBD Health Outcomes
There was a 0.9% increase in the first dispensation of infliximab, either the biosimilar or originator during the first year of follow-up, as well as a 16.2% increase in infliximab dose escalation, a 2.4% decrease in the dispensation of antibiotics, and a 2.6% decrease in the new use of prednisone.
Cyclosporine Bests Infliximab in Long-Term Efficacy for Acute Severe Ulcerative Colitis
The patients that did not undergo colectomy in the infliximab group were more often re-hospitalized because to the need for intravenous corticosteroids at the two-year follow-up compared to the cyclosporine group.
Investigators Identify Several New Predictors for Hepatitis B Vaccine Response in IBD Patients
Individuals that did not respond had a lower percentage of naïve T cells compared to responders, while responders had a lower percentage of Th2 and CD4 central memory subsets before vaccination.